Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511133 | 1.00 | HIF1A (1.00) | HIF1AMEN1NPC1USP2RAB9A | |
| SCHEMBL23523608 | 0.99 | HIF1A (1.00) | HIF1AMEN1NPC1USP2RAB9A | |
| SCHEMBL30511134 | 0.99 | HIF1A (1.00) | HIF1AMEN1NPC1USP2RAB9A | |
| SCHEMBL21777523 | 0.90 | HIF1A (1.00) | HIF1AMEN1KMT2AALDH1A1 | |
| SCHEMBL30511140 | 0.90 | HIF1A (1.00) | HIF1AMEN1KMT2AALDH1A1 | |
| SCHEMBL21777062 | 0.85 | HIF1A (1.00) | HIF1AMEN1NPC1USP2RAB9A | |
| SCHEMBL30511139 | 0.85 | HIF1A (1.00) | HIF1AMEN1NPC1USP2RAB9A | |
| SCHEMBL23564661 | 0.78 | HIF1A (0.79) | HIF1AMEN1NPC1KMT2ALMNA | |
| SCHEMBL23564656 | 0.78 | HIF1A (0.67) | HIF1AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL23523355 | 0.78 | HIF1A (0.79) | HIF1AMEN1NPC1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006283-B2 | HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredient | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-06-11 | — | — | US | disclosed |
| EP-3845516-A1 | NOVEL HIF-1alfa INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | Seoul National University R & DB Foundation (KR) | 2021-07-07 | — | — | EP | disclosed |
| US-20210188753-A1 | NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KP) | 2021-06-24 | — | — | US | disclosed |
| US-20210188753-A1 | NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KP) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006283-B2 | HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredient | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885MEN1 2805/4885NPC1 1931/4885 |
| US-20210188753-A1 | NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | HIF1AN, HIF1A, HYOU1 | HIF1A 2/4885MEN1 3123/4885NPC1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.